莊所 一典 (ショウジョ カズノリ)

Shojo, Kazunori

写真a

所属(所属キャンパス)

医学部 泌尿器科学教室 (信濃町)

職名

助教

経歴 【 表示 / 非表示

  • 2014年04月
    -
    2016年03月

    静岡赤十字病院

  • 2016年04月
    -
    2017年03月

    慶應義塾大学病院

  • 2017年04月
    -
    2018年03月

    国立病院機構 埼玉病院

  • 2018年04月
    -
    2019年03月

    東京歯科大学 市川総合病院

  • 2019年04月
    -
    2020年09月

    済生会横浜市東部病院

全件表示 >>

学歴 【 表示 / 非表示

  • 2008年04月
    -
    2014年03月

    慶應義塾大学, 医学部

    大学, 卒業

 

研究分野 【 表示 / 非表示

  • ライフサイエンス / 腫瘍診断、治療学

  • ライフサイエンス / 泌尿器科学

研究キーワード 【 表示 / 非表示

  • 尿路上皮癌

  • 膀胱癌

 

論文 【 表示 / 非表示

  • Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: Prognostic outcome and comparison with bladder cancer

    Masuda T., Tanaka N., Takamatsu K., Hakozaki K., Takahashi R., Anno T., Kufukihara R., Shojo K., Mikami S., Shinojima T., Kakimi K., Tsunoda T., Aimono E., Nishihara H., Mizuno R., Oya M.

    Journal for ImmunoTherapy of Cancer (Journal for ImmunoTherapy of Cancer)  10 ( 3 )  2022年03月

     概要を見る

    Background The aims of this study were (1) to clarify the impact of tertiary lymphoid structure (TLS) status on the outcome and immunogenomic profile of human clear cell renal cell carcinoma (ccRCC) and (2) to determine phenotypic differences in TLSs between different types of genitourinary cancer, that is, urinary ccRCC and bladder cancer. Methods We performed a quantitative immunohistological analysis of ccRCC tissue microarrays and conducted integrated genome mutation analysis by next-generation sequencing and methylation array analysis. Since the tumor immune microenvironment of ccRCC often differs from that of other cancer types, we analyzed the phenotypic differences in TLSs between ccRCC and in-house bladder cancer specimens. Results Varying distribution patterns of TLSs were observed throughout ccRCC tumors, revealing that the presence of TLSs was related to poor prognosis. An analysis of genomic alterations based on TLS status in ccRCC revealed that alterations in the PI3K-mTOR pathway were highly prevalent in TLS-positive tumors. DNA methylation profiling also revealed distinct differences in methylation signatures among ccRCC samples with different TLS statuses. However, the TLS characteristics of ccRCC and bladder cancer markedly differed: TLSs had the exact opposite prognostic impact on bladder cancer as on ccRCC. The maturity and spatial distribution of TLSs were significantly different between the two cancer types; TLSs were more mature with follicle-like germinal center organization and likely to be observed inside the tumor in bladder cancer. Labeling for CD8, FOXP3, PD-1, and PD-L1 showed marked differences in the diversity of the immune microenvironment surrounding TLSs. The proportions of CD8-, FOXP3-, and PD-L1-positive cells were significantly higher in TLSs in bladder cancer than in TLSs in ccRCC; rather the proportion of PD-1-positive cells was significantly higher in TLSs in ccRCC than in TLSs in bladder cancer. Conclusion The immunobiology of ccRCC is unique, and various cancerous phenomena conflict with that seen in other cancer types; therefore, comparing the TLS characteristics between ccRCC and bladder cancer may help reveal differences in the prognostic impact, maturity and spatial distribution of TLSs and in the immune environment surrounding TLSs between the two cancers.

  • A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations

    Kobayashi H., Kosaka T., Nakamura K., Shojo K., Hongo H., Mikami S., Nishihara H., Oya M.

    BMC Medical Genomics (BMC Medical Genomics)  14 ( 1 ) 245 2021年12月

     概要を見る

    Background: Ductal adenocarcinoma and neuroendocrine cancer are rare subtypes of prostate cancer with poor prognosis and limited therapeutic options. We present the first case of ductal adenocarcinoma having a neuroendocrine phenotype. Case presentation: A 63-year-old man presented with gross hematuria and urinary retention, and his serum prostate-specific antigen level was 4.58 ng/mL. We performed transurethral resection of the prostate, and the diagnosis was ductal adenocarcinoma with a Gleason score of 5 + 4 for acinar adenocarcinoma. Magnetic resonance imaging showed local invasion of left lobe of the prostate and bone metastasis of the left trochanteric section of the femur. Multidisciplinary treatments such as androgen deprivation therapy, chemoradiation therapy, and surgery for metastatic lesions have led to long-term survival. Since next-generation sequencing revealed PTEN and RB1 co-loss and TP53 mutations, we re-evaluated the immunohistochemistry and he was found to be positive for synaptophysin. Conclusions: This is the first Japanese case of ductal adenocarcinoma with a neuroendocrine phenotype. Genetic analysis may help not only guide the therapeutic strategies, but also sometimes with the diagnosis.

  • First case of ductal adenocarcinoma of the prostate with MAP3K1 homozygous deletion

    Shojo K., Kosaka T., Nakamura K., Hongo H., Kobayashi H., Mikami S., Nishihara H., Oya M.

    IJU Case Reports (IJU Case Reports)  4 ( 3 ) 176 - 179 2021年05月

     概要を見る

    Introduction: Ductal adenocarcinoma of the prostate is a rare prostate cancer variant and associated with higher stage and greater risk of mortality. Optimal systemic therapy for metastatic ductal adenocarcinoma is not known. Case presentation: A 67-year-old man presented with ductal adenocarcinoma of the prostate accompanied by multiple lung metastases and advanced bone metastases. We performed channel transurethral resection of the prostate and confirmed the diagnosis of ductal adenocarcinoma of the prostate. DNA sequencing identified a TP53 somatic point mutation (p.Gly245Ser) as the pathogenic variant. Furthermore, a homozygous deletion was observed in mitogen-activated protein kinase kinase kinase 1. The patient received enzalutamide but deceased 5 months after presenting to our institution. Conclusion: To our knowledge, this is the first report of ductal adenocarcinoma of the prostate with a mitogen-activated protein kinase kinase kinase 1 homozygous deletion. Accumulation of whole-exome sequencing data is expected to inform future advances in therapy development.

  • The clinicopathological characteristics of muscle-invasive bladder recurrence in upper tract urothelial carcinoma

    Shigeta K., Matsumoto K., Ogihara K., Murakami T., Anno T., Umeda K., Izawa M., Baba Y., Sanjo T., Shojo K., Tanaka N., Takeda T., Kosaka T., Mizuno R., Mikami S., Kikuchi E., Oya M.

    Cancer Science (Cancer Science)  112 ( 3 ) 1084 - 1094 2021年03月

    ISSN  13479032

     概要を見る

    This study aimed to clarify the clinical characteristics and oncological outcomes of patients with upper tract urothelial carcinoma (UTUC) who developed muscle-invasive bladder cancer (MIBC) after radical nephroureterectomy (RNU). We identified 966 pTa-4N0-2M0 patients with UTUC who underwent RNU and clarified the risk factors for MIBC progression after initial intravesical recurrence (IVR). We also identified 318 patients with primary pT2-4N0-2M0 MIBC to compare the oncological outcomes with those of patients with UTUC who developed or progressed to MIBC. Furthermore, immunohistochemical examination of p53 and FGFR3 expression in tumor specimens was performed to compare UTUC of MIBC origin with primary MIBC. In total, 392 (40.6%) patients developed IVR after RNU and 46 (4.8%) developed MIBC at initial IVR or thereafter. As a result, pT1 stage on the initial IVR specimen, concomitant carcinoma in situ on the initial IVR specimen, and no intravesical adjuvant therapy after IVR were independent factors for MIBC progression. After propensity score matching adjustment, primary UTUC was a favorable indicator for cancer-specific death compared with primary MIBC. Subgroup molecular analysis revealed high FGFR3 expression in non-MIBC and MIBC specimens from primary UTUC, whereas low FGFR3 but high p53 expression was observed in specimens from primary MIBC tissue. In conclusion, our study demonstrated that patients with UTUC who develop MIBC recurrence after RNU exhibited the clinical characteristics of subsequent IVR more than those of primary UTUC. Of note, MIBC subsequent to UTUC may have favorable outcomes, probably due to the different molecular biological background compared with primary MIBC.

  • Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study

    Shigeta K., Matsumoto K., Ogihara K., Murakami T., Anno T., Umeda K., Izawa M., Baba Y., Sanjo T., Shojo K., Tanaka N., Takeda T., Morita S., Kosaka T., Mizuno R., Arita Y., Akita H., Jinzaki M., Kikuchi E., Oya M.

    Urologic Oncology: Seminars and Original Investigations (Urologic Oncology: Seminars and Original Investigations)  40 ( 3 ) 105.e19 - 105.e26 2021年

    ISSN  10781439

     概要を見る

    Objective: The indications of neoadjuvant chemotherapy (NAC) for lymph node-positive upper tract urothelial carcinoma (UTUC) have not been investigated regarding improved survival outcomes. Our specific aim was to compare the clinical outcomes of clinically node-positive UTUC patients who were treated by NAC followed by radical nephroureterectomy (RNU) or upfront RNU followed by adjuvant chemotherapy (AC). Materials and methods: Among 966 UTUC patients, we identified 89 with clinical nodal involvement who received either NAC before RNU nor AC after upfront RNU. Cox proportional hazard models were employed to evaluate the impact of chemotherapy modality on the oncological outcomes. Results: Of the patient cohort, 36 (40.4%) received NAC followed by RNU, whereas 53 (59.6%) underwent RNU followed by AC. Multivariate analysis revealed that tumor size ≥3 cm, clinical T4, and gemcitabine and cisplatin regimen were independent risk factors for disease recurrence, whereas NAC followed by RNU was an independent factor for favorable RFS. Furthermore, regarding cancer-specific survival (CSS), NAC followed by RNU remained an independent factor for favorable CSS. According to Kaplan-Meier analysis, the 1-year and 2-year RFS were 67.9% and 47.0%, respectively, in the NAC+RNU group, which were significantly higher than those in the RNU+AC group (43.9% and 24.6%, respectively, P = 0.006). Moreover, the 1-year and 2-year CSS were 80.5% and 64.2%, respectively, in the NAC+RNU group, which were higher than those in the RNU+AC group (68.6% and 48.2%, respectively, P = 0.016). Conclusion: For node-positive UTUC patients, NAC followed by RNU was more clinically beneficial than RNU followed by AC.

全件表示 >>

総説・解説等 【 表示 / 非表示

  • COVID-19感染を契機に勃起不全を来したと考えられる1例

    茂田 啓介, 森田 伸也, 荘所 一典, 安水 洋太, 田中 伸之, 武田 利和, 松本 一宏, 小坂 威雄, 水野 隆一, 浅沼 宏, 大家 基嗣

    日本性機能学会雑誌 ((一社)日本性機能学会)  37 ( 1 ) 21 - 22 2022年06月

    ISSN  1345-8361

  • 経尿道的前立腺核出術の術後尿道狭窄に関する規定因子の検討

    西田 翔, 萩原 正幸, 荘所 一典, 萩生田 純, 香野 日高, 中川 健

    泌尿器外科 (医学図書出版(株))  33 ( 臨増 ) 872 - 872 2020年06月

    ISSN  0914-6180

  • 術前画像診断で腎血管腫が疑われ腎部分切除を施行した1例

    近内 悠一郎, 宮崎 保匡, 神谷 黎, 荘所 一典, 川崎 英司, 渡邉 昌太郎, 小林 裕章, 石田 勝, 小杉 道男

    泌尿器外科 (医学図書出版(株))  33 ( 5 ) 547 - 547 2020年05月

    ISSN  0914-6180

  • 直腸癌に対する低位前方切除術後にロボット支援腹腔鏡下膀胱全摘除術を施行した1例

    小林 裕章, 廣江 成欧, 岩澤 智裕, 近内 悠一郎, 荘所 一典, 渡邊 昌太郎, 宮崎 保匡, 石田 勝, 清水 正幸, 小杉 道男

    日本泌尿器内視鏡学会総会 ((一社)日本泌尿器内視鏡・ロボティクス学会)  33回   V - 2 2019年11月

  • 腹腔鏡下腎尿管全摘除術の功罪 T3N0M0上部尿路上皮癌における多施設予後解析研究

    茂田 啓介, 菊地 栄次, 萩原 正幸, 荻原 広一郎, 安納 忠嗣, 梅田 浩太, 馬場 優人, 三條 丹星, 荘所 一典, 武田 利和, 松本 一宏, 水野 隆一, 阿部 貴行, 大家 基嗣

    日本癌治療学会学術集会抄録集 ((一社)日本癌治療学会)  57回   O11 - 4 2019年10月

全件表示 >>

研究発表 【 表示 / 非表示

  • 緑内障患者における水平体位によるロボット支援腹腔鏡下膀胱全摘術の検討

    宮崎 保匡, 渡邊 昌太郎, 莊所 一典, 弓削 和之, 石田 勝, 小杉 道男

    日本泌尿器内視鏡学会総会, 

    2020年11月

    (一社)日本泌尿器内視鏡・ロボティクス学会

  • 経尿道的バイポーラ前立腺核出術後の尿道狭窄を引き起こすリスク因子の検討

    莊所 一典, 萩原 正幸, 西田 翔, 伊藤 祐二郎, 萩生田 純, 香野 日高, 中川 健

    日本泌尿器内視鏡学会総会, 

    2019年11月

    (一社)日本泌尿器内視鏡・ロボティクス学会

  • ロボット支援腹腔鏡下根治的前立腺摘除術の神経温存例における健康関連QOLの検討

    莊所 一典, 近内 悠一郎, 小林 裕章, 宮崎 保匡, 石田 勝, 小杉 道男

    日本泌尿器内視鏡学会総会, 

    2019年11月

    (一社)日本泌尿器内視鏡・ロボティクス学会

  • Xp11.2転座型腎細胞癌においてInterleukin-6はprogrammed cell death-1 ligand(PDL1)発現を誘導する

    高松 公晴, 浅沼 宏, 岩佐 俊, 莊所 一典, 寺西 悠, 環 聡, 佐藤 温子, 水野 隆一, 大家 基嗣

    日本小児泌尿器科学会雑誌, 

    2019年06月

    日本小児泌尿器科学会

  • 【腎泌尿器分野における産学連携】前立腺がんにおけるMRIの新たなる応用

    山添 真治, 増田 耕一, 矢ヶ部 浩之, 小橋 由紋子, 最上 拓児, 西田 翔, 莊所 一典, 香野 日高, 中川 健

    腎臓内科・泌尿器科, 

    2019年04月

    (有)科学評論社

全件表示 >>

受賞 【 表示 / 非表示

  • 慶應義塾大学医学部研究奨励費

    2022年

    受賞区分: 塾内表彰等

 

所属学協会 【 表示 / 非表示

  • 日本泌尿器腫瘍学会, 

    2022年
    -
    継続中
  • 日本泌尿器内視鏡・ロボティクス学会, 

    2018年
    -
    継続中
  • 日本泌尿器科学会, 

    2016年
    -
    継続中
  • 日本癌治療学会, 

    2016年
    -
    継続中